Celiac Disease Study

Celiac Disease Trials in Columbus

Aventiv Research is currently participating in a phase 1, Celiac disease study at our Columbus, Ohio location. Celiac disease is a serious autoimmune disease that occurs in genetically predisposed people where the ingestion of gluten leads to damage in the small intestine. Currently there is no drug that is available to treat Celiac disease. The only available option is following a strict gluten-free diet (GFD). Clinical trials are a necessary part of finding treatment for Celiac disease.

Enroll Now

Celiac Disease Study

The primary objective of this clinical trial is to assess the safety and tolerability of single and multiple doses of an investigational drug in patients with Celiac disease. You may be eligible to participate if you:

  • Are 18 to 70 years of age
  • Have been clinically diagnosed with Celiac disease
  • Have followed a GFD for 12 months immediately prior to study entry

Acute Migraine During Prodrome Study

Migraine Trials in Columbus

Aventiv Research is currently participating in the acute migraine study at our Columbus, Ohio location. Migraine attacks have distinct phases, and understanding them can help people manage their disease. The prodrome stage, also known as premonitory or warning phase, marks the beginning of a migraine. Symptoms associated with the earliest stages of a migraine attack, like the fatigue and blurred vision that can accompany the prodrome and aura stages, can serve as warning signs and signal the need for abortive medication.

Enroll Now

Acute Migraine During Prodrome Clinical Trial

The objective of this study is to evaluate the efficacy, safety, and tolerability of an investigational drug compared to placebo for the acute treatment of migraine when administered during the
prodrome. You maybe be eligible to participate in this study if you:

  • Are 18 to 75 years of age
  • Have experienced migraines for 1 year or more, starting before age 50
  • Have had migraines on 2-8 days per month in each of the last 3 months
  • Have migraines that last between 4 and 72 hours if left untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom

Uncontrolled Moderate-to-severe Asthma Study

Asthma Trials in Columbus

Aventiv Research is currently participating in an uncontrolled moderate-to-severe asthma Study at our Dublin, Ohio location. Asthma is a chronic lung disease that affects about 1 in 12 people, and that number continues to grow. The disease inflames and narrows airways, thus causing periods of chest tightness, coughing, shortness of breath, and wheezing on a recurring basis.

Enroll Now

Uncontrolled Moderate-to-severe Asthma Study

The primary objective of this clinical trial is to evaluate the efficacy of safety of an investigational drug in adults with moderate-to-severe uncontrolled asthma compared to a placebo.

You may qualify for this study if you:

  • Are 18 to 65 years of age
  • Have been diagnosed with moderate-to-severe asthma for at least 12 months
  • Have a documented history of at least 1 asthma exacerbation in the past 12 months
  • Are currently treated with a medium-to-high dose inhaled corticosteroid for at least 12 months and on a stable dose for at least 3 months
  • Have a bodyweight of at least 40 kg and BMI less than 35 kg/m2

Uncontrolled Severe Asthma Study

Asthma Trials in Columbus

Aventiv Research is currently participating in an uncontrolled severe asthma Study at our Dublin, Ohio location. Asthma is a chronic lung disease that affects about 1 in 12 people, and that number continues to grow. The disease inflames and narrows airways, thus causing periods of chest tightness, coughing, shortness of breath, and wheezing on a recurring basis.

Enroll Now

Uncontrolled Severe Asthma Study

The primary objective of this clinical trial is to evaluate the efficacy of safety of an investigational drug in adults with severe uncontrolled asthma compared to a placebo.

You may qualify for this study if:

  • You are at least 18 years of age
  • You have had a diagnose of severe asthma for at least 12 months
  • Your asthma is “uncontrolled”, which means that you needed a visit to the emergency department or hospitalization in the past one year and half
  • You have been using standard of care treatment for at least 3 months but you have not responded well to it
  • You can replace your pre-study medication with study-provided investigational medication

Metabolic Acidosis Study

Metabolic Acidosis Trials in Phoenix

Aventiv Research is currently participating in a metabolic acidosis study at our Phoenix, AZ location. Metabolic acidosis is a buildup of acid in your body. Your kidneys help keep the right balance of acids in your body. Your body can have too much acid for two main reasons: 1) your kidneys are not balancing or getting rid of enough acid or 2) your body is making too much acid. Metabolic acidosis is common in people with kidney disease because their kidneys are not filtering their blood well enough. Advances in drug therapy are key to treating this disease in its early stages and preventing further damage.

Enroll Now

Metabolic Acidosis Clinical Trial

The objective of this study is to evaluate the effect of an investigational drug on the progression of chronic kidney disease and to evaluate its safety profile in chronic kidney disease patients with metabolic acidosis. You maybe be eligible to participate in this study if you:

  • Are between 18 and 85 years of age
  • Have been diagnosed with chronic kidney disease
  • Have low serum bicarbonate meeting the study criteria
  • Have stable renal function

FSGS, TR-MCD, and DN Study

FSGS, TR-MCD, and DN Trials in Phoenix

Aventiv Research is currently participating in an FSGS, TR-MCD, and DN study at our Phoenix, AZ location. Currently, there are no approved therapies in the US to specifically treat Focal Segmental Glomerulosclerosis (FSGS) or Treatment Resistant Minimal Change Disease (TR-MCD). Despite current treatments for Diabetic Nephropathy (DN), patients continue to experience progressive loss of kidney function. Given this there is a need to develop new therapies to treat patients with FSGS, TR-MCD, and DN. Advances in drug therapy are key to treating these diseases in their early stages and preventing further damage.

Enroll Now

FSGS, TR-MCD, and DN Clinical Trial

The objective of this study is to evaluate the safety and efficacy of an investigational medication for the treatment of Diabetic Nephropathy (DN), Focal Segmental Glomerulosclerosis (FSGS), and Treatment Resistant Minimal Change Disease (TR-MCD). You may be be eligible to participate in this study if you:

  • Are between 18 and 75 years of age
  • Have been diagnosed with Diabetic Nephropathy (DN)

OR

  • Focal Segmental Glomerulosclerosis (FSGS) AND Treatment Resistant Minimal Change Disease (TR-MCD)

Diabetic Kidney Disease Study

Diabetic Kidney Disease Trials in Phoenix

Aventiv Research is currently participating in a diabetic kidney disease study at our Phoenix, AZ location. Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a serious kidney-related complication of type 1 diabetes and type 2 diabetes. About 25% of people with diabetes eventually develop kidney disease. Advances in drug therapy are key to treating this disease at its early stages and preventing further damage.

Enroll Now

Diabetic Kidney Disease Clinical Trial

The objective of this study is to evaluate the efficacy and safety of an investigational medication in patients with diabetic kidney disease. You maybe be eligible to participate in this study if you:

  • Are at least 18 years of age
  • Have chronic kidney disease AND type 2 diabetes
  • Have stable blood pressure

Cardio-Renal Outcomes in Chronic Kidney Disease Study

Cardio-Renal Outcomes in Chronic Kidney Disease Trials in Phoenix

Aventiv Research is currently participating in an chronic kidney disease study to asses cardio-renal outcomes at our Phoenix, AZ location. Chronic kidney disease (CKD) describes the gradual loss of kidney function. Chronic kidney disease may not become apparent until your kidney function is significantly impaired. Treatment for chronic kidney disease focuses on slowing the progression of the kidney damage, usually by controlling the underlying cause. Advances in drug therapy are key to treating this disease at its early stages and preventing further damage.

Enroll Now

Cardio-Renal Outcomes in Chronic Kidney Disease Clinical Trial

The objective of this study is to assess cardio-renal outcomes from an investigational drug versus placebo in patients with chronic kidney disease. You maybe be eligible to participate in this study if you are:

  • At least 18 years of age
  • Have progressive chronic kidney disease

and do NOT:

  • Currently need an SGLT-2 or SGLT-1/2 inhibitor

Chronic Kidney Disease with IgA Nephropathy or Diabetes Study

Chronic Kidney Disease with IgA Nephropathy or Diabetes Trials in Phoenix

Aventiv Research is currently participating in a study for people who have chronic kidney disease with IgA nephropathy or diabetes at at our Phoenix, AZ location. Chronic kidney disease (CKD) describes the gradual loss of kidney function. Treatment for CKD focuses on slowing the progression of the kidney damage, usually by controlling the underlying cause. Diabetes is the leading cause of kidney failure, accounting for 44% percent of new cases. Current research suggests that control of high blood pressure is a key factor in slowing this disease. IgA nephropathy (also known as Berger’s disease) is one of the most common kidney diseases. It causes damage to the tiny filters inside the kidneys. This damage can cause CKD and can lead to kidney failure. Advances in drug therapies for these indications are key to treating this disease at its early stages and preventing further damage.

Enroll Now

Chronic Kidney Disease with IgA Nephropathy or Diabetes Clinical Trial

The objective of this study is to evaluate the safety, efficacy, tolerability, PD, and PK profile of an investigational drug in patients with chronic kidney disease with IgA nephropathy or diabetes. You maybe be eligible to participate in this study if you are at least 18 years of age, have chronic kidney disease and meet ONE of the three following criteria:

  • be African American with hypertension

OR

  • have IgA nephropathy

OR

  • have type 2 diabetes with hypertension

Lilly BLAZE-1 COVID-19 Antibody Treatment Study

COVID-19 Antibody Treatment Trials in Columbus

Aventiv Research is currently participating in the Eli Lilly BLAZE-1 antibody COVID-19 treatment study at our Columbus, Ohio location. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in the pandemic spread of coronavirus disease 2019 (COVID-19), which in critical cases results in pulmonary failure, respiratory complications, and death. There is an urgent need for effective therapeutics to modify disease outcomes. You can join the fight against COVID-19 by volunteering.

Enroll Now

Lilly BLAZE-1 COVID-19 Antibody Treatment Study

The primary objective of this clinical trial is to characterize the effect of an investigational drug, compared to placebo, on SARS-CoV-2 viral load and viral clearance.  You may qualify for this study if you have recently been diagnosed with COVID-19 or have one or more mild or moderate COVID-19 symptoms such as fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion.

We are specifically looking for people who:

Are at least 18 years of age and satisfy at least one of the following at the time of screening:

  • Are at least 65 years of age
  • Have a BMI  ≥35
  • Have chronic kidney disease
  • Have type 1 or type 2 diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment, or
  • Are ≥ 55 years of age AND have
    • cardiovascular disease, OR
    • hypertension, OR

OR

Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the time of screening:

  • Have a BMI ≥85th percentile for their age and gender
  • Have sickle cell disease
  • Have congenital or acquired heart disease
  • Have neurodevelopmental disorders, for example, cerebral palsy
  • Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
  • Have asthma or reactive airway or other chronic respiratory disease
  • Have type 1 or type 2 diabetes
  • Have immunosuppressive disease, or
    • Are currently receiving immunosuppressive treatment

As a part of our ongoing commitment to protect your health and safety, we’re practicing enhanced safety measures at our clinical research sites.